Risperdal Lawsuit Filings Grow, as Johnson & Johnson Report 18,500 Filings Nationwide

Published on March 21, 2017 by Laurie Villanueva

Text-Size:A A A+

 

Johnson & Johnson continues to face lawsuits over Risperdal, an atypical antipsychotic medication used to treat schizophrenia and other psychiatric disorder in adults and children. According to a recent filing with the U.S. Securities and Exchange Commission (SEC), the company is now named a defendant in at least 18,500 Risperdal lawsuits involving gynecomastia and other side effects allegedly associated with use of the medication.

The majority of claims involving Risprdal are pending in state court litigations underway in Pennsylvania, California, and Missouri. Cases have also been filed in Canada.

“The number of pending product liability lawsuits continues to increase, and the Company continues to receive information with respect to potential costs and the anticipated number of cases,” the SEC filing states. “The Company has established an accrual with respect to product liability litigation associated with RISPERDAL®. Changes to this accrual may be required in the future as additional information becomes available. “

Pennsylvania Risperdal Trials and Verdicts

One of the largest Risperdal litigations is underway in Pennsylvania’s Philadelphia Court of Common Pleas, where more than 5,000 claims have been centralized in a mass tort program. RXInjuryHelp.com indicates that many of the claims pending in that litigation were filed on behalf of male patients who developed gynecomastia after taking Risperdal. The condition, which is characterized by the growth of female-like breasts in men and boys, is thought to be the result of Risperdal’s potential to stimulate the body’s production of prolactin, a hormone that is instrumental in female breast development. High levels of prolactin are also associated with excessive breast growth in males.

Since 2015, several Risperdal lawsuits involving gynecomastia have gone to trial in Philadelphia. Juries have favored plaintiffs in four trials, awarding damages ranging from $70 million to $500,000. Jurors declined damages in a fifth case, while summary judgment was awarded to the defendants in two cases. Undisclosed settlements have also been reached in several Risperdal gynecomastia lawsuits just before trials were scheduled to begin.

Bernstein Liebhard LLP is filing Risperdal lawsuits in state courts around the U.S. If you or a loved one were diagnosed with gynecomastia following treatment with Risperdal, please call (888) 995-5099 to discuss you legal rights with an attorney today.